Product Description
Mechanisms of Action: MGLUR5 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Fragile X Syndrome
Phase 2: Fragile X Syndrome|Dyskinesias|Movement Disorders|Parkinsonian Disorders|Parkinson's Disease|Huntington Disease|Chorea|Obsessive-Compulsive Disorder|Cocaine-Related Disorders|Dyskinesia, Drug-Induced|Alcoholism
Phase 1: Esophagitis, Peptic|Gastroesophageal Reflux|Kidney Diseases|Fragile X Syndrome|Cocaine-Related Disorders|Alcoholic Intoxication|Healthy Volunteers|Alcoholism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HHC-2021-0006 | P1 |
Recruiting |
Alcoholism |
2026-07-31 |
2025-06-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| 2P50AA012870-21 | P2 |
Recruiting |
Alcoholism |
2026-05-31 |
2024-08-16 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
| 2P50AA012870-21 | P1 |
Completed |
Alcoholic Intoxication |
2023-07-13 |
2024-03-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| FX-LEARN | P2 |
Completed |
Fragile X Syndrome |
2022-05-17 |
2023-10-11 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| CAFQ056A02101 | P1 |
Withdrawn |
Cocaine-Related Disorders |
2022-01-03 |
45% |
2021-07-02 |
|
| CAFQ056X2201 | P2 |
Completed |
Cocaine-Related Disorders |
2019-12-16 |
46% |
2020-02-07 |
Primary Completion Date|Study Completion Date |
| HHC-2017-0172 | P1 |
Completed |
Alcoholism |
2019-11-13 |
2019-12-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
| 2017-000736-33 | P2 |
Completed |
Cocaine-Related Disorders |
2019-11-12 |
46% |
2022-03-13 |
Treatments |
| 2011-004867-65 | P1 |
Completed |
Fragile X Syndrome |
2016-08-17 |
2025-07-09 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
| 2011-004378-27 | P2 |
Terminated |
Parkinson's Disease|Dyskinesias |
2015-11-15 |
2025-06-28 |
Treatments |
|
| CAFQ056A2225 | P2 |
Terminated |
Obsessive-Compulsive Disorder |
2014-11-01 |
2019-03-19 |
||
| 2011-001952-12 | P2 |
Completed |
Fragile X Syndrome |
2014-09-10 |
2022-03-13 |
Treatments |
|
| Open-label | P3 |
Terminated |
Fragile X Syndrome |
2014-09-01 |
2019-03-19 |
||
| CAFQ056B2279 | P2 |
Terminated |
Fragile X Syndrome |
2014-09-01 |
2019-03-19 |
Treatments |
|
| 2011-002379-40 | P2 |
Terminated |
Fragile X Syndrome |
2014-08-15 |
2022-03-13 |
Treatments |
|
| 2012-005000-17 | P2 |
Terminated |
Obsessive-Compulsive Disorder |
2014-08-15 |
2022-03-13 |
Treatments |
|
| CAFQ056B2214 | P2 |
Completed |
Fragile X Syndrome |
2014-01-01 |
2019-03-19 |
||
| 2010-022638-96 | P2 |
Completed |
Fragile X Syndrome |
2014-01-06 |
2025-05-06 |
Treatments |
|
| CAFQ056A2217 | P2 |
Completed |
Parkinson's Disease|Dyskinesias|Dyskinesia, Drug-Induced |
2013-10-01 |
2019-03-19 |
Treatments |
|
| CAFQ056A2299 | P2 |
Completed |
Parkinson's Disease|Dyskinesias|Parkinsonian Disorders|Movement Disorders |
2013-10-01 |
2019-03-19 |
Treatments |
|
| CAFQ056B2154 | P1 |
Completed |
Fragile X Syndrome |
2013-10-01 |
2019-03-19 |
Treatments |
|
| ND | P2 |
Terminated |
Dyskinesias |
2013-09-02 |
2025-05-06 |
Treatments |
|
| 2009-013667-19 | P2 |
Completed |
Fragile X Syndrome |
2013-08-14 |
2022-03-13 |
Treatments |
|
| CAFQ056A2212 | P2 |
Completed |
Fragile X Syndrome |
2013-08-01 |
2019-03-19 |
Treatments |
|
| 2011-002074-23 | P2 |
Completed |
Dyskinesias|Parkinson's Disease |
2013-04-24 |
2022-03-13 |
Treatments |